Table 3.

Receiver operating characteristic analyses of different non-invasive scores in prediction of advanced fibrosis (stage III/IV) in NAFLD.

Scores	Overall (n = 368)			Conventional NAFLD cohort (n = 143)			Morbidly obese NAFLD cohort (n = 225)
	AUROC	95% CI	p value	AUROC	95% CI	p value	AUROC	95% CI	p value
NAFLD Fibrosis Score (NFS)	0.750	0.680–0.820	<0.001	0.868	0.803–0.934	<0.001	0.873	0.802–0.944	<0.001
Modified NFS (NFSmod)a	0.838	0.776–0.899	<0.001	0.869	0.803–0.934	<0.001	0.888	0.817–0.960	<0.001
FIB-4 Score	0.904	0.861–0.948	<0.001	0.871	0.805–0.937	<0.001	0.887	0.796–0.979	<0.001
APRI Score	0.848	0.801–0.895	<0.001	0.726	0.636–0.817	<0.001	0.845	0.754–0.935	<0.001
AST/ALT Ratio	0.710	0.639–0.782	<0.001	0.812	0.729–0.895	<0.001	0.698	0.586–0.810	<0.05
BARD Score	0.708	0.639–0.778	<0.001	0.833	0.758–0.908	<0.001	0.760	0.647–0.873	<0.01

NAFLD non-alcoholic fatty liver disease, FIB-4 fibrosis 4 score, AST aspartate aminotransferase, ALT alanine aminotransferase, APRI aspartate aminotransferase to platelet ratio index.

^aModified NFS with BMI limited to 40 kg/m².